Financial Daily from THE HINDU group of publications
Thursday, Jul 04, 2002

Port Info

Group Sites

Corporate - Announcements

Ranbaxy gets US FDA nod for Lisinopril

Our Bureau


RANBAXY Pharmaceuticals Inc (RPI) has received a final approval from the US-FDA to manufacture and market Lisinopril+Hydrochlorothiazide tablets, indicated for the treatment of hypertension.

Based on bio-equivalence studies, it has been deemed to be bio-equivalent and therapeutically equivalent to Prinizide tablets by Merck Research Laboratories, a company release said here on Wednesday.

A wholly-owned subsidiary of Ranbaxy Laboratories Ltd (RLL), RPI has also received approval from the US-FDA to manufacture and market Lisinopril tablets USP, 2.5 mg, 5 mg, 10 mg, 20 mg and 40 mg also for hypertension, either alone as initial therapy or concomitantly with other classes of anti-hypertensive agents.

This product too was said to be bio-equivalent and therapeutically equivalent to Zestril tablets, an RLL note said. The significance of the approval is that all strengths of this combination product will be available along with Lisinopril as a single entity formulation.

Send this article to Friends by E-Mail

Stories in this Section
German pharma co plans research in India on AIDS

Ranbaxy gets US FDA nod for Lisinopril
Hepatitis B vaccine prices slashed
SEBI panel findings on buyback by month-end
ICAI renames auditing practices panel — Regulatory bodies, public to have a say henceforth
Jargons ajar
HDFC subscribes to 6.9 pc preference shares of RIL
Sasken converts Japanese arm into branch office
Sesa Goa seeks to dispose of Sirsaim unit
ACC to sell stake in Intl Ferrites in Rs 40-cr deal
Idea Cellular-BPL merger in a limbo
IOC denies imposing fresh riders on HPL
Alfa Laval India to be hub for global projects business
Singareni Collieries hopes to wipe out losses this fiscal
Sanofi-Synthelabo eyes 20% growth in topline
M.K. Sinha takes over at NCL
Alstom board reconstituted

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line